Trials / Terminated
TerminatedNCT00144833
Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects
A Phase III, Randomized, Controlled, Open-Label, Multicentre, Three Arm Study to Compare the Efficacy and Safety of a Dual-Boosted HIV-1 Protease Inhibitor Regimen of Fosamprenavir/Lopinavir/Ritonavir 1400mg/533mg/133mg Twice Daily and an Increased Dosage Regimen of FPV/RTV 1400mg/100mg BID Versus the Standard Dosage Regimen of FPV/RTV 700mg/100mg BID for 24 Weeks in Multiple-PI Experienced, HIV-Infected Adults Experiencing Virological Failure
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
For HIV-infected individuals with highly resistant viruses, higher drug levels may be required to block the virus. This study investigates that concept by comparing the efficacy of standard fosamprenavir/ritonavir to an increased dose of boosted fosamprenavir and to a combination of fosamprenavir (increased dose)/lopinavir/ritonavir.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | fosamprenavir/ritonavir (700mg/100mg BID) | |
| DRUG | fosamprenavir/ritonavir (1400mg/100mg BID) | |
| DRUG | fosamprenavir/lopinavir/ritonavir (1400mg/533mg/100mg BID) |
Timeline
- Start date
- 2005-03-01
- First posted
- 2005-09-05
- Last updated
- 2007-11-12
Locations
42 sites across 9 countries: Australia, Belgium, Canada, France, Germany, Greece, Italy, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00144833. Inclusion in this directory is not an endorsement.